<DOC>
	<DOCNO>NCT02795949</DOCNO>
	<brief_summary>The continuous increase bacterial resistance rate slow arrival new therapeutic option turn antibiotic crisis . One strategy propose stewardship program try change situation describe worldwide use antibiotic lowest possible antimicrobial spectrum . Enterobacteriaceae bacteremia good example strategy would apply . The empirical treatment nosocomial bacteremia Enterobacteriaceae comprise several case one two antibiotic antipseudomonal activity , much less common desirable subsequent change narrower spectrum antibiotic base susceptibility data ( `` de escalation '' ) . This safety de escalation base expert advice observational study , efficacy safety question many clinician therefore use low desire . In fact , recent systematic review Cochrane Library conclude randomized study support practice need . Investigators propose `` real clinical practice-based '' randomize trial compare efficacy safety continue antipseudomonal agent vs. de-escalation accord pre-specified rule , patient bacteraemia due Enterobacteriaceae .</brief_summary>
	<brief_title>Study Reduced Antibiotic Treatment v Broad Spectrum Betalactam Patients With Bacteremia Enterobacteriaceae</brief_title>
	<detailed_description />
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Enterobacteriaceae Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Clavulanic Acid</mesh_term>
	<mesh_term>Clavulanic Acids</mesh_term>
	<mesh_term>Imipenem</mesh_term>
	<mesh_term>Ertapenem</mesh_term>
	<mesh_term>Ceftazidime</mesh_term>
	<mesh_term>beta-Lactams</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<mesh_term>Ampicillin</mesh_term>
	<mesh_term>Cefuroxime</mesh_term>
	<mesh_term>Piperacillin , tazobactam drug combination</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Cefepime</mesh_term>
	<mesh_term>Aztreonam</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<criteria>1 . ≥18 year old hospitalize patient bacteremia source isolation enterobacteria blood culture . 2 . Active empiric treatment antipseudomonal betalactamic 48 hour symptoms sepsis blood culture . 3 . Microorganism susceptible least one treatment experimental arm . 4 . Patients intravenous treatment least 5 day . 5 . Patients sign inform consent form . 1 . Palliative care life expectance &lt; 90 day . 2 . Pregnancy lactation period . 3 . To isolate Extendedspectrum βlactamases produce Enterobacteriaceae 4 . Late randomization &gt; 48 hour enterobacteriaceae blood culture´s identification 5 . Severe neutropenic ( &lt; 500 céls/mm3 ) randomization . 6 . Treatment infection &gt; 28 day ( endocarditis osteomyelitis ) meningitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Enterobacteriaceae</keyword>
	<keyword>Bacteremia</keyword>
	<keyword>Escalation</keyword>
	<keyword>Bacterial resistance</keyword>
	<keyword>Bloodstream infection</keyword>
	<keyword>Recurrence</keyword>
</DOC>